A novel system of peptidergic regulation  by Karelin, Andrei A et al.
Minireview
A novel system of peptidergic regulation
Andrei A. Karelin, Elena Yu. Blishchenko, Vadim T. Ivanov*
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10,
117871 Moscow, GSP-7, Russia
Received 7 April 1998
Abstract Systematic analysis of structure and biological
activity of peptide components of tissue extracts and biological
fluids allows us to formulate a novel concept of a peptidergic
regulatory system, complementary to the conventional regulatory
systems (i.e. nervous, endocrine and paracrine systems). Accord-
ing to that concept, the proteolytic degradation of tissue proteins
carried out by a specific and regulated system of tissue-specific
enzymes and protein substrates gives rise to a large group of
peptides, which we define as tissue-specific peptide pool. As a
result, functional proteins provide their proteolytically derived
fragments for maintaining tissue homeostasis.
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1. Introduction
It is well established that biologically active peptides are
mediators of a large number of regulatory systems. Several
thousands of the substances involved in signal transduction
in nervous, immune, endocrine and paraendocrine and other
systems have been identi¢ed and characterized. Most of these
peptides are cleaved from speci¢c precursors by trypsin-like
processing enzymes and released from cells. No other function
than giving birth to the peptides is known for these precur-
sors. The secreted peptides further interact with speci¢c recep-
tors localized on the target cell surface and trigger the signal
transduction into the cells. In this way the activity of the
majority of peptide hormones, parahormones and neurotrans-
mitters, i.e. ‘classical’ peptide bioregulators, is realized.
The biological function of this group of substances has been
examined in detail and described in a number of reviews and
monographs (e.g. [1^3]). At the same time, there are many
biologically active peptides that do not correspond to the
above mentioned features of ‘classical’ peptide bioregulators.
The present minireview deals with that group of peptides.
2. Proteolysis of functional proteins in vitro leads to formation
of biologically active peptides
For several decades it has been known that in vitro treat-
ment of proteins by various proteinases results in generation
of peptides exhibiting pronounced biological e¡ects. The ¢rst
observation of the activity of proteolytic protein fragments
was made in 1941, when treatment of blood plasma proteins
with pepsin gave rise to a mixture of substances inducing
histamine release from mast cells [4]. At that time there was
no experimental means to interpret the phenomenon in struc-
tural terms. Further work along similar lines has been con-
tinued in a number of laboratories con¢rming the conclusion
that in vitro enzymatic digestion of biological preparations,
including both tissue homogenates and individual proteins,
leads to formation of biologically active peptides. More
than 300 protein fragments have been identi¢ed and se-
quenced [5]. In contrast to ‘classical’ peptide bioregulators,
this group of peptides is formed upon proteolysis of proteins
with well established function in vivo.
At present bioactive fragments of functional proteins in-
clude peptides derived from L-casein (so called L-casomor-
phins), hemoglobin, myelin basic protein, gluten, serum albu-
min, cytochrome c, lactoferrin and some other proteins [5,6].
Several peptides originally obtained by proteolysis in vitro,
i.e. opioid-like hemoglobin fragments (VV-hemorphin-7 and
LVV-hemorphin-7 [7]), neurotensin-like fragment of albumin
(HRP-1 [8]) and L-casomorphin-8 [9], were later identi¢ed in
biological £uids or tissues in vivo. The presence of myelin
basic protein fragments in biological preparations was also
shown by means of immunochemical methods, however the
sequences of peptide-like immunoreactive material have not
been established [10].
At the same time, only a small fraction of peptides derived
from in vitro proteolysis of functional proteins was identical
to peptides derived in vivo from the same precursors. This
discrepancy might be partially due to the technical aspects
of isolation. Screening of compounds formed upon in vitro
proteolysis, as a rule, is aimed at isolation of most active
components, independently of their content in the mixture
obtained, while screening of endogenous protein fragments
in biological sources commonly results in isolation of the
most abundant species.
3. Tissue-speci¢c peptide pool ^ the result of endogenous
proteolytic degradation of functional proteins
In spite of the fact that molecular fractions of tissue ex-
tracts have been routinely used as a source of ‘classical’ pep-
tide bioregulators, the components of these fractions were not
subjected to systematic structural studies until the early 1990s.
It is generally accepted that proteolytic enzymes non-specif-
ically digest the proteins normally present in the tissue after
ful¢lling their function. In this case, the tissue extracts should
contain a ‘random’, physiologically inert set of protein frag-
ments. The content of these peptides should correspond to the
level of protein precursors and the stability of these proteins
to proteolytic degradation. Based on this concept the frag-
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ments of hemoglobin identi¢ed in the course of isolation of
LH-RH were considered artifacts, in spite of their biological
activity [11,12]. Analogous views led to the search for a spe-
ci¢c precursor of neokyotorphin, a pentapeptide identical to
the C-terminal segment of the K-chain of hemoglobin isolated
from bovine brain [13]. The broad spectrum of neuromodula-
tory e¡ects shown for this peptide [6] did not allow us to
consider it an artifact, on the one hand, or as a hemoglo-
bin-derived fragment, on the other.
Since 1993 a large number of endogenous fragments of
functional proteins have been isolated and the ¢rst results of
systematic structural studies of components of low molecular
fractions of tissue extracts have been obtained. Chromato-
graphic analysis of the components of extracts of bovine
[14,15] and rat [16,17] brain, human cerebellum [17,18], bovine
bone marrow [14] as well as the lysate and the supernatant of
primary culture of human erythrocytes [6,19] demonstrated
that these sources contain a panel of compounds. The number
of substances corresponding to the chromatographic peaks,
distinguishable by means of computer analysis of the elution
pro¢les, varies within the 200^800 range, depending on the
biological source. Both the content and the composition of
components characteristic for each tissue was highly repro-
ducible and strongly tissue-dependent. Most of the compo-
nents were identi¢ed as peptides. The overall content of pep-
tides per 1 g of tissue comprises 0.02^0.5% of the total
preparation weight [15,20]. Judging from their sequences these
peptides are derived from a limited group of functional pro-
teins or from non-de¢ned protein precursors. Some of them
are present at levels of 50^80 nmol/g of tissue [6,15,21,22],
which is much higher than the typical content of ‘classical’
peptides in most tissues, i.e. 1^50 pmol/g of tissue [23,24].
Most of the components of tissue extracts were identi¢ed as
hemoglobin fragments. In spite of the fact that hemoglobin, as
a major blood protein, is widely distributed in the organism,
the content and the composition of hemoglobin-derived pep-
tides is also tissue-speci¢c. For instance, the overall levels of
hemorphins, i.e. the peptides belonging to the 32^40 site of L-
globin, vary signi¢cantly in di¡erent biological tissues and
£uids. The total level of hemorphins ranges from 100^500
nM/g of tissue in the rat heart and lung extracts [22] to 0.1^
1 nM/g of tissue or less in bovine bone marrow [14], rat spleen
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Fig. 1. Peptides derived from the N-terminus of human L-globin. Erythrocyte membrane separates the peptides found inside the erythrocyte
and in the supernatant of the erythrocyte primary culture.
Table 1
Distinctive features of peptidergic regulatory systems
Property Peptidergic regulatory system
Nervous Endocrine and paracrine Tissue-speci¢c peptide pool
Family Neurotransmitters Hormones Fragments of functional proteins
Precursor Speci¢c protein precursor Speci¢c protein precursor Functional protein
Type of processing Discrete site-speci¢c processing Discrete site-speci¢c processing Action of tissue proteinases
Content (nM/g tissue) 0.001^1.0 0.001^1.0 0.1^100
Type of regulation Synaptic secretion Extracellular secretion Alteration of the level in the
tissue
Mechanism of action Binding to receptors in
synaptic membranes





Time range of action seconds^minutes minutes^hours hours^days
Biological role Transmission of nerve impulse Regulation of physiological processes in the
tissue or the whole organism
Maintenance of tissue
homeostasis
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[22] or blood plasma [25]. Analogously, the content of neo-
kyotorphin in rat lung tissue is 10^15-fold higher than in the
rat brain [21]. Brain extracts also contain fragments of neuro-
speci¢c proteins [15,16], the spleen extract is enriched with
fragments of L-actin [26].
A number of peptides from tissue extracts were discovered
earlier and found to be active in a variety of biological test
systems. For instance, hemorphins are active in basic opioid
tests: inhibition of binding of opioid ligands to brain mem-
branes, induction of naloxone-dependent analgesia in rats in
vivo and contractile activity at the guinea pig ileum [7]. Neo-
kyotorphin was shown to terminate the hibernation of ground
squirrels and to enhance the inward potential-dependent Ca2
current in cardiac myocytes of frog [27]. A number of hemo-
globin fragments display hemopoietic activity [14]. All these
data provided a critical mass for formulating the concept
considering two patterns of peptide-mediated regulation.
The ¢rst is mediated by the ‘classical’ peptide bioregulators
formed from speci¢c precursors by means of speci¢c proteo-
lytic enzymes and produced by specialized cells. The other
implies the action of biologically active fragments of function-
al proteins. According to that concept each tissue contains a
speci¢c set of proteins, which are cleaved after completion of
their function by tissue-speci¢c proteolytic enzymes giving rise
to a large group of peptides which can be de¢ned as a ‘tissue-
speci¢c peptide pool’. The composition and the content of
components in the pool are characteristic for the given organ
or tissue.
At the same time, signi¢cant changes in composition and
content of components of tissue-speci¢c peptide pools were
shown to accompany several pathologies. For instance, the
content of some intraerythrocyte hemoglobin fragments in-
creased more than 10-fold in the cells of patients with Hodg-
kin’s disease [28]. Alterations in content of long (more than
25 amino acid residues in length) hemoglobin fragments were
detected in cerebellum of patients with Alzheimer’s disease
[17,18] and hippocampus of rats subjected to induced brain
ischemia [17]. Alterations of the level of myelin basic protein
fragments were shown to accompany several CNS pathologies
of newborn children [14]. The composition and the content
of components of tissue-speci¢c peptide pools should be con-
sidered an important characteristic of the state of the tis-
sue.
4. Formation of the components of tissue-speci¢c peptide pools
The identi¢ed components of tissue-speci¢c peptide pools
can be divided into two groups: (i) the fragments of intra-
cellular proteins; (ii) the fragments of extracellular and mem-
brane-associated proteins. Some fragments of intracellular
functional proteins were shown to act inside the cell. In par-
ticular, the fragment (24^62) of neurogranin (a calmodulin-
binding protein kinase C (pkC) substrate [29]), exhibited cal-
modulin-binding activity. This fragment is also a good sub-
strate of pkC [30]. Neurogranin belongs to a large group of
B-50 proteins, that includes a number of calmodulin-binding
substrates of pkC (F-1, GAP-43, neuromodulin). The N-ter-
minal fragment of GAP-43-PIP inhibits phosphorylation of
GAP-43 by pkC [31].
Since hemoglobin-derived peptides are the largest group of
protein fragments found in all tissue extracts studied so far,
comprising 30^90% of the total number of sequenced protein
fragments [6,14^18], the patterns of endogenous hemoglobin
fragmentation could be outlined in some detail. Hemoglobin
degradation inside the erythrocytes seems to proceed in sev-
eral consecutive steps: at the ¢rst stage K- and L-chains of
hemoglobin are cleaved in the middle segment giving rise to
peptides 60^80 amino acid residues in length. Study of myo-
globin proteolysis has shown that removal of hemin makes the
middle segment of that protein much more sensitive to the
action of proteolytic enzymes with di¡erent speci¢city [32].
Bearing in mind the analogy of spatial structures of hemoglo-
bin chains and myoglobin, in particular, of the site sensitive to
the proteolytic attack in myoglobin with the putative primary
splitting sites of K- and L-globin, we consider apoglobins the
most probable substrates of erythrocyte proteinases.
The products of primary splitting are subjected to a second-
ary splitting stage at sites containing two hydrophobic resi-
dues, i.e. Phe33^Leu34 and Leu105^Leu106 in the case of the K-
chain and at Phe41^Phe42 and Leu110^Val11 for the L-chain.
The resultant fragments are further degraded, primarily by
amino- and carboxypeptidases forming a set of stepwise N-
and C-terminally shortened peptides 20^30 amino acid resi-
dues in length [6,19,20]. Formation of long peptides within
erythrocytes is followed by tertiary splitting, accompanied
by the release of smaller, 4^20-membered fragments into the
surrounding medium.
The above described pattern is illustrated in Fig. 1. After
secondary splitting of the L-chain at Phe41^Phe42 the resultant
fragment is cleaved at the Leu31TVal33 site giving rise to the
family of hemorphins, the dipeptide LV and the fragment (1^
30). The former peptides are released from the erythrocytes,
while the latter is subjected to C-terminal shortening inside
the cells. The alternative tertiary splitting of the L-(1^30) pep-
tide at Val11^Thr12 leads to peptide families derived from the
segments (1^11) and (12^31). According to that description
the peptides belonging to the L-(1^11) family might be formed
by two complementary pathways: by means of C-terminal
shortening of the fragment (1^30) inside the erythrocytes or
by tertiary splitting at the erythrocyte membrane followed by
excretion from the cells. In summary, proteolysis of hemoglo-
bin within the erythrocytes takes place in three main stages.
The intermediate products of these stages are subjected to N-
and C-terminal shortening by amino- and carboxypeptidases
giving rise to ‘ladders’ of structurally related peptides.
Altogether, amino acid sequences of 32 intraerythrocyte
peptides and 36 peptides released from human erythrocytes
have been established [6,19]. The structural set of the released
peptides di¡ers signi¢cantly from that observed in tissue
(brain, bone marrow) extracts and inside the erythrocytes.
In particular, a novel family corresponding to the (84^95)
segment of the hemoglobin K-chain was discovered in the
supernatant, as well as a novel pattern of formation of the
peptides corresponding to L-chain segment (12^31). The re-
lated family found in bovine brain extract [15] is formed upon
cleavage of L-globin (14^28) at the Asp20^Glu21 site giving rise
to two groups of both N- and C-terminally shortened pep-
tides. In contrast, in the erythrocytes the tertiary splitting
takes place at Val11^Thr12 (instead of Leu13^Trp14) and the
resultant fragments are in turn cleaved at two sites (Val17^
Asn18 and Asp20^Glu21) forming two families of overlapping
peptides. Moreover, erythrocytes excrete a novel subfamily of
hemorphins, V-hemorphins, not found in other biological
sources. Ten of the 36 peptides are known for their biological
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e¡ects, while most of the rest structurally overlap with other
bioactive hemoglobin fragments.
By analogy with hemoglobin we suggest that other intra-
cellular proteins are also subjected to stepwise degradation
leading to formation of short peptides further excreted from
the cells. Analysis of structures of peptides derived from cy-
tochrome c oxidase, glutamate-ammonium ligase, glyceralde-
hyde-3-phosphate dehydrogenase and found in brain extract
allows us to assume that the basic mechanisms of formation
of these peptides are similar to that of hemoglobin fragments
[14,15]. In particular, peptides are cleaved at sites containing
two hydrophobic residues, analogous to the secondary split-
ting of hemoglobin and the resultant products are further
trimmed by amino- and carboxypeptidases at N- and C-ter-
mini.
5. Biological activities of the components of tissue-speci¢c pools
Of more than 250 sequenced components of tissue-speci¢c
pools, 60^65 peptides were shown to be biologically active
[6,14]. The available data suggest that the activity of at least
several groups of the components of the peptide pools (such
as hemorphins [7] or HRP-1 [8], etc. [5]) might be realized
through the same receptors as with neurotransmitters or hor-
mones (such as opiate, neurotensin, bombesin). Typically, the
binding a⁄nities of the pool components are by several orders
of magnitude lower than for ‘classical’ peptide bioregulators
and their content in blood and other biological £uids is not
normally su⁄cient for transduction of signals in the organism
[19,25]. However, these peptides are present in higher amounts
in tissues [21,22], in contrast to blood plasma and cerebrospi-
nal £uid [25,33]. Therefore their potency is expected to be
expressed mainly at the tissue level. Several structurally re-
lated families of fragments of functional proteins, for instance
hemorphins [34,35] and casomorphins [36], were shown to
induce cytolysis and to inhibit proliferation of tumor cells,
i.e. to exhibit e¡ects analogous to ‘classical’ ligands of opioid
receptors [37,38]. In contrast to opioid activities of hemoglo-
bin fragments, their oncolytic activity is comparable to that of
‘classical’ opioids. At the same time, the molecular targets of
the majority of the tissue-speci¢c peptides are not established.
In spite of that, they exhibit pronounced e¡ects at the cellular
level. Neokyotorphin and, to a lesser degree, des-Arg-neokyo-
torphin were shown to stimulate proliferation of tumor cells.
In contrast to neokyotorphin, its fragment induces cytolysis of
tumor cells [21,39]. The presence of high amounts of neokyo-
torphin in lung carcinoma suggests its involvement in tumor
development [40]. It was recently found that two groups of K-
globin fragments, (1^32)-(1^30) and (106^141)-(110^141), in-
duce a 30^60% increase of proliferative tumor cell growth [41].
The activity of hemoglobin fragments is concentration-de-
pendent. For instance, peptides K-(12^24) and K-(12^23) cause
a 35^45% decrease of live tumor cell number at 1036^1037 M.
At the same time, these peptides show no reliable e¡ect on
viability or proliferation of the same tumor cells in a 1038^
1039 M concentration range and stimulate proliferation at
10310 M up to 60%. Similarly, long intraerythrocyte frag-
ments of hemoglobin increase tumor cell growth in a 1036^
1038 M concentration range but show a slight growth-inhib-
itory e¡ect at lower concentrations.
Since tumor cells are a rather simple and convenient model
for evaluation of in vitro activity of di¡erent compounds,
including proteins, peptide hormones, or neurotransmitters,
we carried out a primary search for bioactive peptides derived
from functional proteins using this particular test system. The
available literature data speak of the involvement of such
peptides in regulation of proliferation of normal cells. For
example, VV-hemorphin-5 slightly inhibits proliferation of
red bone marrow cells (20% growth inhibition, or 3 times
less than that of tumor cells [34]). Neokyotorphin stimulates
proliferation of proadipocytes [42], peptide K-(33^38) exhibits
immunostimulatory activity [43] and a number of short hemo-
globin fragments increase the proliferative rate of lymphocytes
treated with radiation or cytostatic drugs [14]. The tetrapep-
tide AcSDKP, initially isolated from fetal bovine bone mar-
row extract, inhibits proliferation of hemopoietic progenitor
cells [44]. LVV-hemorphin-3 was shown to restore PHA-in-
duced proliferation of T-cells pretreated with immunosuppres-
sive factors produced by HL-60 leukemia cells [45]. A neuro-
tensin-related peptide, analogous to neurotensin, stimulates
histamine release from mast cells [46].
In other words, the biological potency of the components
of tissue-speci¢c peptide pools is reliably documented at the
cellular level, at least, in vitro. It is worth mentioning that
components of the tissue-speci¢c peptide pools have several
features in common with the so called cytomedines, a term
proposed in the early 1980s for the components from low
molecular mass fractions of the total tissue extracts that
are applied in clinical practice as tissue-restorative pre-
parations [47,48]. Like cytomedines, the fragments of func-
tional proteins might participate in maintenance or restora-
tion of homeostasis of the given tissue in case of
pathology.
6. Tissue-speci¢c peptide pools as a novel system of peptidergic
regulation
The above described data strongly suggest that the process
of protein elimination should not be considered a random
proteolysis leading to amino acids in turn employed for var-
ious metabolic purposes. Instead, it is a complex process car-
ried out by a speci¢c and regulated system of tissue-speci¢c
enzymes and protein substrates. As already mentioned, this
process results in formation of a panel of peptides which we
de¢ne as a tissue-speci¢c peptide pool. In contrast to ‘classi-
cal’ peptide bioregulators, in particular, hormones or para-
hormones such as neurotensin or substance P, which are se-
creted by speci¢ed cells, the components of tissue-speci¢c
peptide pools are produced by all cells comprising the tissue.
The composition and the content of each component in the
pool are speci¢c for the given organ or tissue.
Based on the studies of receptor properties of opioid-like
fragments of functional proteins, i.e. hemorphins or casomor-
phins [7,49], it can be generalized that components of tissue-
speci¢c peptide pools modulate the availability of hormonal
receptors to their ‘true’ ligands. In this case, the high content
of fragments of functional proteins might compensate for
their relatively low binding parameters. Tissue-speci¢c pools
contain peptides exhibiting a variety of e¡ects, sometimes of
opposite signs (see above) and might be considered polyfunc-
tional and polyspeci¢c ‘bu¡ers’ providing the basic hormonal
signals for tissue cells and regulating the availability of the
signals to the given tissue. One can also envisage cases of
inverse regulation, when changes in the e⁄ciency of local
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proteolytic processes take place as a result of hormonal sig-
nals.
At the same time, the molecular mechanisms of action of
the majority of the components of tissue-speci¢c pools are
unknown. It might well be that they are not restricted to
modulation of the activity of peptide hormones. Some of
the peptides could be involved in regulation of cell adhesion
[50,51] and the fragments of intracellular proteins, such as
calmodulin [17] or neurogranin [15,16], might participate in
the regulation of signal transduction at the intracellular level.
The following examples provide a clue to the possible en-
dogenous role of the components of tissue-speci¢c peptide
pools. We have demonstrated recently that K-globin fragment
K-(2^32) restores proliferation of red bone marrow cells pre-
treated with epirubicin, being inactive in the normally prolif-
erating cells [41]. Similar data were obtained for the L-globin
fragment (1^10), that was shown to restore proliferation of
lymphocytes in mice treated with 5-£uorouracil [14]. It seems
that the activity of such peptides is predominantly expressed
in damaged cells or cells subjected to ‘unfavorable’ conditions.
The data on the therapeutic e¡ects of the preparations based
on peptide components of tissues, Cerebrolysin or ‘cytome-
dins’ (see above), indicate their ability to restore, at least
partially, the normal function of the tissue. For instance,
the action of Cerebrolysin in the case of Alzheimer’s disease
is due to restoration of the connection between the neurons,
and, as a result, to a notable improvement of brain activity
[48]. It seems that the function of tissue-speci¢c peptides can
be essentially formulated as maintenance of the equilibrium
between the growing, di¡erentiating, normally functioning
and dying cells of the given tissue and, consequently, as com-
pensating for the e¡ects caused either by exogenous damaging
agents (such as cytostatic drugs) or by endogenous regulatory
factors.
Both the composition and the content of tissue-speci¢c pep-
tides depend strongly on the content and the availability of
protein substrates to proteolytic enzymes as well as on the
activity of proteolytic enzymes in the given tissue. Accord-
ingly, several pathologies are accompanied by changes in com-
position and content of the fragments of functional protein in
tissues [14^18,28,40,41]. Notwithstanding the clinical and bio-
chemical di¡erences, these pathologies have a common prin-
cipal feature ^ they involve alterations in tissue homeostasis or
metabolic state of the cells, independently of the nature of the
disease: cell transformation [40,41], tissue atrophy (Alzheim-
er’s disease and ischemia [16^18]) or impaired lymphoprolif-
eration (Hodgkin’s disease [28]). Activity of the components
of tissue-speci¢c peptide pools in cell cultures in vitro shows
that their biological role might be due to prevention of tumor
cell growth or to control of viability, growth and di¡erentia-
tion of cells of the tissues, i.e. to maintenance of tissue homeo-
stasis.
Summarizing the data described above we suggest that frag-
ments of functional proteins form a novel system of peptider-
gic regulation. However, there is certainly no strict borderline
between the peptides regulating the function of nervous, en-
docrine or paracrine systems and the peptides derived from
functional proteins (Table 1). On the one hand, one cannot
exclude that precursors of ‘classical’ peptide bioregulators ex-
hibit certain not yet discovered in vivo functions. It is also
known that their processing is not always trypsin-like and
highly speci¢c [52,53]. Some of the ‘classical’ peptide bioregu-
lators are not secreted from the speci¢ed cells, for instance,
‘tissue hormones’ angiotensin II and bradykinin are formed in
the tissues from extracellular proteins (T-kininogens) [54].
Moreover, as already described, a number of the components
of tissue-speci¢c peptide pools bind to the same receptors as
peptide hormones and exhibit similar biological e¡ects
[7,8,49]. The above mentioned features are common to ‘clas-
sical’ peptide bioregulators and tissue-speci¢c peptides.
On the other hand, any regulatory system should belong to
a concrete systemic level, i.e. to the whole organism, to a
given organ, tissue or isolated cells. Typically, the major
role of a hormonal regulatory system is in ensuring the ‘co-
operative work’ of di¡erent organs and tissues in order to
maintain the integrity of the whole organism and in providing
thereby an adequate reaction of the given organism to exter-
nal signals. In contrast, the overall data on features of the
components of tissue-speci¢c peptide pools, i.e. (i) high level
in tissues, as opposed to that in blood plasma, (ii) tissue
speci¢city, and (iii) activity in cell cultures, suggest that the
function of such peptides is realized mainly at the tissue and
cellular levels. Stability of the composition and the content of
such peptides in tissues at normal conditions suggests their
participation in the maintenance of the appropriate ratio of
dividing, di¡erentiating and dying cells of the corresponding
tissue.
On the other hand, the mediators of conventional regula-
tory systems (nervous, endocrine or immune system), as a
rule, can be seen as inducing changes in the state of the tissue
by transducing changes of the membrane potential, by stim-
ulating or inhibiting secretion of bioactive compounds, etc.,
while the function of the components of tissue-speci¢c pools
might be due to bringing back the tissue to stationary con-
dition. It can also be suggested that induction of the hor-
mone-mediated e¡ects takes place exclusively when the appro-
priate level of hormones in tissue is attained, i.e. tissue-speci¢c
peptides restrict the possibility of ‘occasional’ alterations of
tissue state and consequently maintain the tissue homeostasis
[6]. As a result, both systems maintain the equilibrium of bio-
logical processes at the level of the whole organism.
Since the change of the proteolytic activity within the tissue
is a relatively slow process, compared with the action of hor-
mones and neurotransmitters, we believe that the components
of tissue-speci¢c peptide pools should be predominantly in-
volved in long-term regulation of tissue or organism state.
On the basis of the above discussed data it can also be
assumed that the proteolysis-based peptidergic system is phy-
logenetically a more ancient regulatory system than the nerv-
ous and endocrine systems. This proposal follows from the
fact that the peptide pool does not necessarily require the
entire organism to express its activity. Most of its inherent
potency could be employed at the cellular level. Moreover,
some of the fragments of intracellular proteins might regulate
a variety of responses within a single cell, i.e. such mechanism
could be applied even to unicellular organisms.
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